文献速递消化道肿瘤与早癌食管胃疾病与幽门螺杆菌

胃腺癌腹膜转移的多重分析揭示新靶点及预测治疗反应的分子亚型

Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.
PubMed 文献 · Gut · 2019-06-06

该研究对44例胃腺癌腹膜转移标本进行全外显子组和全转录组测序,并与TCGA原发胃腺癌比较,发现CDH1、TAF1突变及6q缺失、19号染色体获得等独特改变,鉴定出「间质样」和「上皮样」两个分子亚型,两者化疗反应率分别为31%和71%,间质样亚型高表达TIM-3、galectin-9、VISTA和TGF-β等潜在免疫治疗靶点。

要点

  • 腹膜转移灶较原发灶更常见CDH1、TAF1突变及6q缺失、19号染色体获得。
  • 间质样亚型化疗反应率31%,上皮样亚型71%。
  • 间质样亚型高表达TIM-3、galectin-9、VISTA和TGF-β等免疫靶点。

核心结论

  • 研究揭示了胃腺癌腹膜转移细胞独特的突变图谱、拷贝数变异和基因表达谱,并定义了与化疗耐药/反应相关的分子亚型。
  • 发现了新的治疗靶点及免疫检查点蛋白,具有转化至临床的潜力。

研究设计与样本

  • 对44例腹膜转移标本(来自43例腹膜转移患者)进行全外显子组测序和全转录组测序。
  • 整合分析外显子组、转录组、免疫特征、临床和病理表型,并与TCGA原发胃腺癌比较。

主要发现

  • 腹膜转移灶较原发胃腺癌更频繁出现CDH1和TAF1突变、6q缺失和19号染色体获得。
  • 侵袭性腹膜转移表型相关改变包括TP53、CDH1、TAF1和KMT2C突变增加、『时钟样』突变特征水平升高、全基因组加倍增加、染色体不稳定性(特别是拷贝数丢失)、微环境重编程、细胞周期通路富集、MYC激活和免疫反应受损。
  • 整合分析鉴定出两个主要分子亚型:『间质样』和『上皮样』,两者化疗反应率分别为31%和71%。
  • 对化疗反应较差的『间质样』亚型患者高表达免疫检查点TIM-3、其配体galectin-9、VISTA和TGF-β,作为潜在治疗性免疫靶点。

关键数值与推荐

  • 『间质样』亚型化疗反应率为31%,『上皮样』亚型为71%。

临床怎么用

  • 腹膜转移分子亚型(间质样 vs 上皮样)与化疗反应相关,间质样亚型化疗反应率较低(31% vs 71%)。
  • 间质样亚型高表达TIM-3、galectin-9、VISTA和TGF-β,为潜在免疫治疗靶点。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Peritoneal carcinomatosis (PC) occurs frequently in patients with gastric adenocarcinoma (GAC) and confers a poor prognosis. Multiplex profiling of primary GACs has been insightful but the underpinnings of PC's development/progression remain largely unknown. We characterised exome/transcriptome/immune landscapes of PC cells from patients with GAC aiming to identify novel therapeutic targets. DESIGN: We performed whole-exome sequencing (WES) and whole transcriptome sequencing (RNA-seq) on 44 PC specimens (43 patients with PC) including an integrative analysis of WES, RNA-seq, immune profile, clinical and pathological phenotypes to dissect the molecular pathogenesis, identifying actionable targets and/or biomarkers and comparison with TCGA primary GACs. RESULTS: We identified distinct alterations in PC versus primary GACs, such as more frequent CDH1 and TAF1 mutations, 6q loss and chr19 gain. Alterations associated with aggressive PC phenotypes emerged with increased mutations in TP53, CDH1, TAF1 and KMT2C, higher level of 'clock-like' mutational signature, increase in whole-genome doublings, chromosomal instability (particularly, copy number losses), reprogrammed microenvironment, enriched cell cycle pathways, MYC activation and impaired immune response. Integrated analysis identified two main molecular subtypes: 'mesenchymal-like' and 'epithelial-like' with discriminating response to chemotherapy (31% vs 71%). Patients with the less responsive 'mesenchymal-like' subtype had high expression of immune checkpoint T-Cell Immunoglobulin And Mucin Domain-Containing Protein 3 (TIM-3), its ligand galectin-9, V-domain Ig suppressor of T cell activation (VISTA) and transforming growth factor-β as potential therapeutic immune targets. CONCLUSIONS: We have uncovered the unique mutational landscape, copy number alteration and gene expression profile of PC cells and defined PC molecular subtypes, which correlated with PC therapy resistance/response. Novel targets and immune checkpoint proteins have been identified with a potential to be translated into clinics.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang R, Song S, Harada K, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2019. PMID: 31171626. doi:10.1136/gutjnl-2018-318070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。